SWP
ZVRA icon

Stratos Wealth Partners’s Zevra Therapeutics ZVRA Stock Holding History

Stratos Wealth Partners’s Portfolio ZVRA Stock Details ZVRA Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$5.85M Hold
408,000
– – 0.06% 309
2026
Q1 		$3.8M Sell
408,000
-1,000
-0.2% -$9.01K 0.04% 389
2025
Q4 		$3.66M Buy
409,000
+180,000
+79% +$1.7M 0.04% 399
2025
Q3 		$2.18M Buy
229,000
+9,000
+4% +$90.3K 0.03% 510
2025
Q2 		$1.94M Sell
220,000
-90,000
-29% -$730K 0.03% 502
2025
Q1 		$2.32M Sell
310,000
-25,840
-8% -$205K 0.04% 410
2024
Q4 		$2.8M Sell
335,840
-82,800
-20% -$707K 0.04% 390
2024
Q3 		$2.91M Buy
418,640
+348,400
+496% +$2.36M 0.04% 371
2024
Q2 		$344K Hold
70,240
– – 0.01% 1043
2024
Q1 		$407K Hold
70,240
– – 0.01% 970
2023
Q4 		$460K Buy
70,240
+40
+0.1% +$187 0.01% 901
2023
Q3 		$338K Hold
70,200
– – 0.01% 963
2023
Q2 		$358K Hold
70,200
– – 0.01% 884
2023
Q1 		$386K Hold
70,200
– – 0.01% 779
2022
Q4 		$322K Hold
70,200
– – 0.01% 865
2022
Q3 		$438K Sell
70,200
-357
-0.5% -$2.02K 0.01% 739
2022
Q2 		$315K Sell
70,557
-10
-0% -$46 0.01% 905
2022
Q1 		$355K Sell
70,567
-1,290
-2% -$8.21K 0.01% 927
2021
Q4 		$626K Buy
71,857
+900
+1% +$8.03K 0.01% 731
2021
Q3 		$662K Buy
+70,957
New +$715K 0.02% 657
2018
Q4 		– Sell
-8
Closed -$1K – 2557
2018
Q3 		$1K Buy
+8
New +$625 ﹤0.01% 2900
2018
Q2 		– Sell
-8
Closed -$1K – 2636
2018
Q1 		$1K Hold
8
– – ﹤0.01% 3049
2017
Q4 		$0 Buy
+8
New +$483 ﹤0.01% 2838

Other funds holding ZVRA

BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
WP
Woodline Partners San Francisco, California $32.4B AUM 58.5% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
NCM
Nantahala Capital Management New Canaan, Connecticut $3.01B AUM 119.46% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
D.E. Shaw & Co
D.E. Shaw & Co New York $210B AUM 57.28% 1-Year Est. Return
Qube Research & Technologies (QRT)
Qube Research & Technologies (QRT) London, United Kingdom $108B AUM 37.29% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return

Stratos Wealth Partners's ZVRA Position: Q2 2026 in Review

Stratos Wealth Partners held its Zevra Therapeutics (ZVRA) position steady in Q2 2026 at 408,000 shares worth $5.85M. The position accounts for 0.06% of the portfolio, ranked #309.

Stratos Wealth Partners first reported a position in ZVRA in Q4 2017 and has held it in 23 quarters since. 157 funds tracked by Wall St. Rank hold ZVRA as of Q2 2026.

  • Stratos Wealth Partners held 408,000 shares of Zevra Therapeutics worth $5.85M as of Q2 2026.
  • Stratos Wealth Partners left its Zevra Therapeutics share count unchanged in Q2 2026.
  • Zevra Therapeutics made up 0.06% of Stratos Wealth Partners's portfolio in Q2 2026, its #309 holding.
  • Stratos Wealth Partners first reported a position in Zevra Therapeutics in Q4 2017 and has held it in 23 quarters since.
  • 157 funds tracked by Wall St. Rank held Zevra Therapeutics as of Q2 2026.

Based on Stratos Wealth Partners's 13F filing for Q2 2026, filed 11 Aug 2026.